Tvardi Therapeutics (69C) Price & Analysis

Compare

1 Followers

69C Stock Chart & Stats

Day’s Range― - ―

52-Week Range€6.60 - €33.75

Previous CloseN/A

Volume0.00

Average Volume (3M)34.00

Market Cap

€324.51M

Enterprise Value€156.52M

Total Cash (Recent Filing)€40.99M

Total Debt (Recent Filing)€254.00K

Price to Earnings (P/E)―

Beta0.58

Next Earnings

May 12, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding9,377,433

10 Day Avg. Volume100

30 Day Avg. Volume34

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€52.39

Price Target Upside55.23% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsBlinded interim analysis trial has revealed a positive trend on forced vital capacity (FVC), and an independent monitoring committee has opined that the trial should continue as is.

Financial RunwayTVRD has $41 million in cash, providing a financial runway into the fourth quarter of 2026, past important phase 2 readouts.

Market PotentialSTAT3 inhibition can curb a range of inflammatory and fibrotic pathways, potentially driving a superior FVC response versus standard of care.

Bears Say

Market CompetitionThe base case assumes TTI-101 has a profile that is at least superior to BMS' admilparant.

Product DevelopmentTTI-101 could potentially match PLRX's bexotegrast in efficacy.

Tvardi Therapeutics News

BTIG biotech analyst holds a dinner meeting

Biotech Analyst Harrison holds a dinner meeting with Tvardi Therapeutics (TVRD) to discuss Emerging Trends in Pulmonary Fibrosis...

15d ago

TVRD

3 Best Stocks to Buy Now, 9/11/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

29d ago

CATX

ONON

Nine new option listings and one option delisting on September 10th

New option listings for September 10th include American Bitcoin Corp (ABTC), LightPath (LPTH), Kindly MD Inc (NAKA), Palatin...

30d ago

ABTC

LPTH

Tvardi Therapeutics: Buy Rating Driven by Promising TTI-101 Trial Prospects

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on TVRD stock, giving a Buy rating on August...

1M ago

TVRD

Tvardi Therapeutics Reports Q2 2025 Financial Results

Tvardi Therapeutics Inc. ( ($TVRD) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

TVRD

Eight option delistings on August 18th

Option delistings effective August 18th include Q32 Bio Inc (QTTB), Hyperdynamics Corp (HYPD), Bionano Genomics (BNGO), Allurion Technologies...

2M ago

ABTS

ALUR

Tvardi Therapeutics Faces Legal and Financial Risks from Exclusive Forum Provision

Tvardi Therapeutics Inc. (TVRD) has disclosed a new risk, in the Share Price & Shareholder Rights category. Tvardi...

2M ago

TVRD

Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, “We are on track for topline data in the...

2M ago

TVRD

Tvardi Therapeutics expects cash to fund operations into Q4 2026

Cash runway anticipated to be sufficient to fund operations into Q4 2026 Published first on TheFly – the...

2M ago

TVRD

Tvardi Therapeutics management to meet with Piper Sandler

Meeting to be held on July 22 in Boston and on July 23 in New York hosted by...

3M ago

TVRD

Tvardi Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Tvardi Therapeutics (TVRD) with an Outperform rating and $62 price target The company...

3M ago

TVRD

Tvardi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $52 price target Published first...

3M ago

TVRD

Coinbase, Datadog, Tvardi, CF, Conagra: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($COIN) ), ( ($DDOG) ), ( ($TVRD) ), ( ($CF)...

4M ago

CAG

Tvardi Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $78 price...

4M ago

TVRD

69C FAQ

What was Tvardi Therapeutics Inc.’s price range in the past 12 months?

Tvardi Therapeutics Inc. lowest stock price was €6.60 and its highest was €33.75 in the past 12 months.

What is Tvardi Therapeutics Inc.’s market cap?

Tvardi Therapeutics Inc.’s market cap is €324.51M.

When is Tvardi Therapeutics Inc.’s upcoming earnings report date?

Tvardi Therapeutics Inc.’s upcoming earnings report date is May 12, 2025 which is 151 days ago.

How were Tvardi Therapeutics Inc.’s earnings last quarter?

Currently, no data Available

Is Tvardi Therapeutics Inc. overvalued?

According to Wall Street analysts Tvardi Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tvardi Therapeutics Inc. pay dividends?

Tvardi Therapeutics Inc. does not currently pay dividends.

What is Tvardi Therapeutics Inc.’s EPS estimate?

Tvardi Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tvardi Therapeutics Inc. have?

Tvardi Therapeutics Inc. has 9,377,433 shares outstanding.

What happened to Tvardi Therapeutics Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tvardi Therapeutics Inc.?

Currently, no hedge funds are holding shares in DE:69C

Tvardi Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-93.85%

Trailing 12-Months

Asset Growth

-39.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tvardi Therapeutics Inc.

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

Tvardi Therapeutics (69C) Earnings & Revenues

Historic Earnings Reports

69C Stock 12 Month Forecast

Average Price Target

€52.39

▲(55.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","68":"€68","22.25":"€22.3","37.5":"€37.5","52.75":"€52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67.43175738,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€67.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.389288426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€52.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.76744666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€39.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,22.25,37.5,52.75,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.55,35.23321210615384,37.91642421230769,40.599636318461535,43.28284842461538,45.96606053076923,48.64927263692307,51.33248474307692,54.015696849230764,56.69890895538461,59.382121061538456,62.0653331676923,64.74854527384615,{"y":67.43175738,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.55,34.07609910969231,35.60219821938461,37.12829732907692,38.654396438769226,40.180495548461536,41.70659465815385,43.23269376784616,44.75879287753846,46.284891987230765,47.810991096923075,49.337090206615386,50.8631893163077,{"y":52.389288426,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.55,33.10518820461538,33.660376409230764,34.21556461384615,34.77075281846154,35.32594102307692,35.881129227692306,36.43631743230769,36.99150563692307,37.546693841538456,38.10188204615385,38.65707025076923,39.212258455384614,{"y":39.76744666,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.449,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.985,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.964,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.507,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.507,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.507,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >